Oncocross Co., Ltd.
Research Oncocross Co., Ltd. (382150.KQ) on Bullrun: market cap KRW 39.03B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker382150.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorTechnology
- IndustrySoftware - Infrastructure
- CurrencyKRW
- Market capKRW 39.03B
- Financial periodQ2 2026
- RevenueKRW 58.12M
- Net incomeKRW 1.01B
- Free cash flow-KRW 2.04B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 39.03B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 39.03B | n/a | n/a | n/a |
Dividend history
About Oncocross Co., Ltd.
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis.
Related stock research
Other Technology stocks
Frequently asked questions
What is Oncocross Co., Ltd.'s market cap?
Oncocross Co., Ltd.'s market capitalization is KRW 39.03B.
What does Oncocross Co., Ltd. do?
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis.